Sun Pharma gets US nod for leukaemia drugNovember 17th, 2009 MUMBAI - Indian drug major Sun Pharmaceuticals Tuesday said it has secured tentative approval from the United States Food and Drugs Administration for the generic version of Gleeven, used to treat chronic myeloid leukaemia. The drug will be available in two strengths of 100 mg and 400 mg and the market size for them is estimated at nearly $900 million, the pharmaceuticals company said in a filing with the stock exchanges.
Lexicon Pharma says its irritable bowel syndrome drug LX1031 met study goal; shares jumpNovember 13th, 2009 Lexicon says IBS drug met mid-stage study goalTHE WOODLANDS, Texas — Lexicon Pharmaceuticals Inc. said Friday an irritable bowel syndrome drug candidate met its goals in a mid-stage clinical trial.
Teva Pharmaceutical receives FDA approval for generic version of heartburn drug PrevacidNovember 10th, 2009 more images
more imagesTeva gets FDA approval for generic PrevacidNEW YORK — Teva Pharmaceutical Industries Ltd. said Tuesday the Food and Drug Administration approved its generic version of the heartburn drug Prevacid.
India, EU to resolve generic drugs expots tangleNovember 6th, 2009 NEW DELHI - The European Union (EU) is not opposed to exports of generic medicine by Indian companies through its ports, European Commissioner for Trade Catherine Ashton said here Friday. Answering a query on the confiscation of Indian consignments of generic medicine in European ports, which were bound for other countries, she said EU would soon resolve the issue.
BioCryst takes bigger 3Q loss after starting late-stage tests of IV flu treatment peramivirOctober 29th, 2009 more images
more imagesBioCryst 3Q loss grows as peramivir tests continueBIRMINGHAM, Ala. — BioCryst Pharmaceuticals Inc.
Hospira profit climbs on sales of generic chemotherapy treatment and other specialty drugsOctober 27th, 2009 more images
more imagesChemotherapy drug sales boost Hospira 3Q profitLAKE FOREST, Ill. — Hospira Inc.
Shire says FDA reaffirms 5-year market exclusivity period for ADHD drug VyvanseOctober 26th, 2009 Shire says FDA reaffirms Vyvanse exclusivityNEW YORK — Shire PLC said the U.S. Food and Drug Administration reaffirmed a prior decision to give the attention-deficit-hyperactivity disorder drug Vyvanse five-years of market exclusivity.
Oxidized form of vitamin A offers beneficial treatment for ulcerative colitisOctober 2nd, 2009 WASHINGTON - Retinoic acid-the oxidized form of vitamin A-may be a beneficial treatment for people suffering from ulcerative colitis and other irritable bowel diseases, according to a new study. Published in the Journal of Leukocyte Biology, the study has specifically found that retinoic acid helps suppress out-of-control inflammation, a hallmark of active ulcerative colitis.
FDA tells doctors reformulated blood thinner heparin will be safer, but less potentOctober 1st, 2009 FDA tells doctors new heparin formula less potentWASHINGTON — The Food and Drug Administration is alerting doctors that a widely used blood thinner has been reformulated to improve its safety, though the change could open the door to dosing errors. The FDA said Thursday new heparin vials scheduled to begin shipping next week will be 10 percent less potent than the original blood thinner.
Antidepressant found to be just as effective as placebo in child pain reliefOctober 1st, 2009 WASHINGTON - A new study has shown that the antidepressant amitriptyline is just as effective as placebo in treating pain-predominant gastrointestinal disorders in children. "Many pharmaceutical products are prescribed for off-label use in children due to the lack of clinical trials testing the efficacy of the drugs in children and adolescents.
Decks cleared for Orchid to market anti-infectives in USSeptember 25th, 2009 CHENNAI - Decks have been cleared for the city-based Orchid Chemicals and Pharmaceuticals for marketing the generic versions of Zosyn antibiotic, with a US district court rejecting rival Wyeth Laboratories' motion for a restraint on the sale of the drug. Wyeth had filed a suit in the District Court of Columbia against the US Food and Drug Administration's (FDA) decision to grant Orchid permission to sell generic Zosyn, chemically Piperacillin-Tazobactam, claiming the drug could harm critically ill patients.
1.25 mn capsules of new swine flu drug enter Indian marketSeptember 25th, 2009 NEW DELHI - As swine flu cases continue to surge in the country, a pharma company Friday announced that it has pushed 1.25 million capsules of the drug to chemists across the country to combat the virus and it would be ready with 10 million such drugs by mid-October. We have launched Natflu capsules (generic version of Tamiflu - Oseltamivir), the first cure for swine flu to be available against medical prescription at designated chemists across India, said V.C.
Adolor buys rights to Eli Lilly drug, plans studies on opioid bowel dysfunctionSeptember 21st, 2009 Adolor buys rights to Eli Lilly drugEXTON, Pa. — Biotechnology company Adolor Corp.
FDA approves J&J's Cypher stent for use in smaller blood vesselsSeptember 21st, 2009 FDA approves smaller version of J&J stentBRIDGEWATER, N.J. — Medical product conglomerate Johnson & Johnson said Monday the Food and Drug Administration approved a smaller version of its drug-coated stent, Cypher.
Soluble fibre 'effective in treating irritable bowel syndrome'August 28th, 2009 LONDON - A new study by researchers from Utrecht University in the Netherlands has suggested that a soluble fibre supplement called psyllium should be the first line of attack in treating irritable bowel syndrome (IBS). In the study, researchers compared adding bran, psyllium and a dummy supplement to sufferers' diets.
